Cargando…

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.

OBJECTIVE: The transfer of abacavir, a new nucleoside inhibitor, and amprenavir, a new protease inhibitor, used for the treatment of human immunodeficiency virus, has been studied in the ex vivo human placental model. METHODS: The ex vivo human placental model used C14 antipyrine to determine the tr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bawdon, R E
Formato:	Texto
Lenguaje:	English
Publicado:	1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1784821/ https://www.ncbi.nlm.nih.gov/pubmed/9972485 http://dx.doi.org/10.1002/(SICI)1098-0997(1998)6:6<244::AID-IDOG4>3.0.CO;2-B

Ejemplares similares

Ex Vivo Human Placental Transfer of Anti-Human Immunodeficiency Virus Compounds
por: Bawdon, Roger E.
Publicado: (1997)

Ex vivo human placental transfer of trovafloxacin.
por: Casey, B, et al.
Publicado: (2000)

Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
por: Magee, Kevin P., et al.
Publicado: (1996)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
por: Swindells, Susan, et al.
Publicado: (2005)

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
por: Blaine-Sauer, Simon, et al.
Publicado: (2023)

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir
por: Yu, Yuqi, et al.
Publicado: (2015)

Transfer of meropenem in the ex vivo human placenta perfusion model.
por: Hnat, Michael, et al.
Publicado: (2005)

The Bidirectional Transfer and Fetal Vascular Pressure Changes Due to the Presence of [Formula: see text] I-Labeled Inhibin A in the ex-vivo Human Placental Model
por: Bawdon, Roger E., et al.
Publicado: (2003)

In Vitro and Ex Vivo Inhibition of Human Telomerase by Anti-HIV Nucleoside Reverse Transcriptase Inhibitors (NRTIs) but Not by Non-NRTIs
por: Hukezalie, Kyle R., et al.
Publicado: (2012)

Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function
por: Fraichard, Camille, et al.
Publicado: (2021)

The Metabolism and Transplacental Transfer of Oseltamivir in the Ex Vivo Human Model
por: Worley, Kevin C., et al.
Publicado: (2008)

Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations
por: Chen, Jianzhong, et al.
Publicado: (2014)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

In Silico Modeling for Ex Vivo Placental Transfer of Morphine
por: Ho, Harvey, et al.
Publicado: (2022)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

Bidirectional Transfer Study of Polystyrene Nanoparticles across the Placental Barrier in an ex Vivo Human Placental Perfusion Model
por: Grafmueller, Stefanie, et al.
Publicado: (2015)

Transplacental passage of vancomycin in the ex vivo human perfusion model.
por: Hnat, Michael D, et al.
Publicado: (2004)

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages
por: Borrajo, Ana, et al.
Publicado: (2017)

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model
por: Mandelbrot, Laurent, et al.
Publicado: (2019)

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
por: Yin, Dwight E., et al.
Publicado: (2020)

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
por: Subeha, Mahbuba R., et al.
Publicado: (2020)

Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
por: Jochmans, Dirk, et al.
Publicado: (2010)

Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro
por: Samuels, Tina L., et al.
Publicado: (2023)

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
por: Keiser, Philip H, et al.
Publicado: (2005)

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Novel acyclic nucleoside analogues as inhibitors of HIV-1 RT
por: Singh, Anuradha, et al.
Publicado: (2012)

Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication
por: Barral, Karine, et al.
Publicado: (2011)

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060
por: Hobbs, Charlotte V., et al.
Publicado: (2016)

Transfer of protease inhibitors to inhibit cartilage destruction
por: van der Laan, WH, et al.
Publicado: (2001)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Placental Passage of Protopine in an Ex Vivo Human Perfusion System
por: Spiess, Deborah, et al.
Publicado: (2022)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

In Vitro and Ex Vivo Evaluations on Transdermal Delivery of the HIV Inhibitor IQP-0410
por: Ham, Anthony S., et al.
Publicado: (2013)

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling
por: Schalkwijk, Stein, et al.
Publicado: (2017)

Current and Novel Inhibitors of HIV Protease
por: Pokorná, Jana, et al.
Publicado: (2009)

The Reverse Transcription Inhibitor Abacavir Shows Anticancer Activity in Prostate Cancer Cell Lines
por: Carlini, Francesca, et al.
Publicado: (2010)

Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo
por: Nzuza, Sanelisiwe, et al.
Publicado: (2017)

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
por: Bourgi, Kassem, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_10lm1k2u166q9urmkh2ivpdndh